|Chemical and physical data|
|Molar mass||278.348 g/mol g·mol−1|
|3D model (JSmol)|
AC-262536 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM). Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a Ki of 5nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the anabolic action of testosterone, but only around 27% of its potency as an androgen.
- Piu, F; Gardell, LR; Son, T; Schlienger, N; Lund, BW; Schiffer, HH; Vanover, KE; Davis, RE; Olsson, R; Bradley, SR (2008). "Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator". The Journal of Steroid Biochemistry and Molecular Biology. 109 (1–2): 129–37. doi:10.1016/j.jsbmb.2007.11.001. PMID 18164613.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|